The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response
Michelle Leech(Monash Institute of Medical Research), Eric F. Morand(Novartis (Switzerland)), Pamela Hall(Monash University), Leilani L. Santos(Royal Women's Hospital), A. Richard Kitching(Monash Health), Yuan Yang(Xihua University), April Dacumos(Monash Medical Centre), J R Xue(Monash Medical Centre), Ming‐Qing Li(Shanghai Jiao Tong University)
Cited by 30
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726